Get the Stockscreener App
2.55
2.82%
0.07
Cabaletta Bio Inc stock is traded at $2.55, with a volume of 4.29M.
It is up +2.82% in the last 24 hours and up +9.91% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.48
Open:
$2.44
24h Volume:
4.29M
Relative Volume:
1.17
Market Cap:
$233.24M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.5361
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-29.36%
1M Performance:
+9.91%
6M Performance:
+119.83%
1Y Performance:
-44.32%
1-Day Range:
$2.30
$2.555
1-Week Range:
$2.30
$3.575
52-Week Range:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.55 | 226.83M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
How supply chain issues affect Cabaletta Bio Inc. stock2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - newser.com
What technical signals suggest for Cabaletta Bio Inc. stock2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Is Cabaletta Bio Inc. stock a contrarian buy2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Will Cabaletta Bio Inc. stock outperform Nasdaq indexSwing Trade & Free Risk Controlled Daily Trade Plans - newser.com
Cabaletta Bio Reports Breakthrough Results in Autoimmune Disease Trials - MyChesCo
How Cabaletta Bio Inc. stock reacts to oil pricesPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - fcp.pa.gov.br
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Treasury Yields & Daily Chart Pattern Signal Reports - newser.com
How Cabaletta Bio Inc. stock reacts to bond yields - newser.com
Will Cabaletta Bio Inc. see short term momentumMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
Tools to assess Cabaletta Bio Inc.’s risk profile2025 Trade Ideas & Stock Portfolio Risk Management - newser.com
Can Cabaletta Bio Inc. stock resist sector downturnsBull Run & Consistent Return Investment Signals - fcp.pa.gov.br
How Cabaletta Bio Inc. stock compares to growth peersOptions Play & Safe Capital Growth Plans - fcp.pa.gov.br
Can Cabaletta Bio Inc. hit a new high this monthWeekly Risk Summary & Long-Term Capital Growth Ideas - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Analyst Upgrade & Weekly Return Optimization Plans - newser.com
Applying sector rotation models to Cabaletta Bio Inc.Quarterly Portfolio Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest - Yahoo Finance
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December - The Manila Times
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Is Cabaletta Bio Inc. stock attractive for long term wealth building2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsMarket Activity Summary & Capital Protection Trade Alerts - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Cabaletta Bio’s Remarkable Surge: Positive Clinical Data and Elevated Price Targets - StocksToTrade
Cabaletta Bio Stock Price Rises After Positive Clinical Data Announcement - timothysykes.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Update - MarketBeat
Jennison Associates LLC Boosts Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
Cabaletta Bio’s RESET-MS Study: A New Frontier in Multiple Sclerosis Treatment - MSN
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? - MSN
Can Cabaletta Bio Inc. stock maintain operating marginsEarnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Cabaletta Bio Stock Climbs Amid Positive Clinical Developments - StocksToTrade
Cabaletta Bio Poised for Growth Amid Positive Clinical Data Releases - timothysykes.com
Cabaletta Bio (NASDAQ:CABA) Price Target Raised to $30.00 - MarketBeat
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):